کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9275377 | 1222287 | 2005 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروب شناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The activity of dalbavancin, a new semi-synthetic lipoglycopeptide antibiotic, was evaluated in comparison with other antibacterial agents against 1229 Gram-positive organisms collected from medical centres in Latin America. Dalbavancin was the most potent compound tested against isolates of Staphylococcus aureus (MIC50, 0.06 mg/L) and coagulase-negative staphylococci (MIC50, 0.03 mg/L), independently of methicillin susceptibility. Dalbavancin inhibited all Streptococcus pneumoniae isolates at ⤠0.06 mg/L. Dalbavancin also demonstrated excellent activity against β-haemolytic (MIC50, ⤠0.008 mg/L) and viridans group (MIC50, 0.016 mg/L) streptococci. All vancomycin-susceptible Enterococcus spp. isolates were inhibited by dalbavancin at ⤠0.25 mg/L, but some vancomycinresistant Enterococcus spp. isolates were only inhibited by dalbavancin levels of â¥8 mg/L. Dalbavancin exhibited excellent activity against isolates of Corynebacterium spp. and Listeria spp. Dalbavancin may provide an important therapeutic option for Gram-positive infections, excluding those caused by enterococci with VanA-type resistance.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Microbiology and Infection - Volume 11, Issue 2, February 2005, Pages 95-100
Journal: Clinical Microbiology and Infection - Volume 11, Issue 2, February 2005, Pages 95-100
نویسندگان
A.C. Gales, H.S. Sader, R.N. Jones,